Abstract Number: 0633 • ACR Convergence 2023
Prediction of Progressive Fibrosing Interstitial Lung Disease in Systemic Sclerosis Patients: Insight from the CRDC Cohort Study
Background/Purpose: Systemic sclerosis (SSc) patients can develop progressive fibrosing interstitial lung disease (PF-ILD), linked to a poor outcome. This study aims to establish a reliable…Abstract Number: 0790 • ACR Convergence 2023
Transcriptomic Analyses of Lung Tissues Reveals Potential Key Genes Associated with Progression of Systemic Sclerosis-Interstitial Lung Disease (SSc-ILD)
Background/Purpose: SSc-ILD is the leading cause of death in SSc affecting around 50% of the patients. Lung tissue of patients with early-stage SSc-ILD is characterized…Abstract Number: 1173 • ACR Convergence 2023
Prognostic Biomarkers and Radiological Features of Idiopathic Inflammatory Myopathy Associated Interstitial Lung Disease
Background/Purpose: Idiopathic inflammatory myopathy (IIM) is a chronic inflammatory disorder involved in skeletal muscles. Interstitial lung disease (ILD) as an organ lesion is a common…Abstract Number: 1700 • ACR Convergence 2023
Incidence and Risk Factors for New Onset of Interstitial Lung Disease in Systemic Sclerosis: A EUSTAR Analysis
Background/Purpose: Although prevalence of interstitial lung disease (ILD) in systemic sclerosis (SSc) and associated risk factors are established, less is known about its incidence and…Abstract Number: 2120 • ACR Convergence 2023
Independent and Combined Impact of Interstitial Lung Disease and Airway Disease on Rheumatoid Arthritis Disease Activity and Infections
Background/Purpose: How interstitial lung disease (ILD) and airway disease (AD) independently affect the clinical course of rheumatoid arthritis (RA) is unclear since previous studies conflated…Abstract Number: 2574 • ACR Convergence 2023
Are Patients Classified as IPAF More Likely to Also Meet SLE Criteria by 2019 EULAR/ACR Than by SLICC?: An Abstract
Background/Purpose: Interstitial pneumonia with autoimmune features (IPAF) is a research classification proposed by the European Respiratory Society and American Thoracic Society Task Force for those…Abstract Number: 0289 • ACR Convergence 2023
Markers of Endothelial Damage Are Elevated in Patients with Dermatomyositis Associated Interstitial Lung Disease and Associated with Low Paraoxonase-1 Activity
Background/Purpose: Damage to the vascular endothelium is implicated in the pathogenesis of idiopathic inflammatory myopathies (IIM) and its associated interstitial lung disease (ILD), with microvascular…Abstract Number: 0643 • ACR Convergence 2023
Progression of Interstitial Lung Disease in Systemic Sclerosis Does Not Predict Further Progression
Background/Purpose: In clinical practice, we often wait for progression of interstitial lung disease (ILD) in systemic sclerosis (SSc) to initiate or escalate therapy. Similarly, progressive…Abstract Number: 0808 • ACR Convergence 2023
Real-World Disease Monitoring Patterns in Rheumatoid Arthritis-Associated Interstitial Lung Disease in the Veterans Affairs Health Care System
Background/Purpose: There are currently no clinical practice guidelines for monitoring RA-associated interstitial lung disease (RA-ILD). Pulmonary function tests (PFTs) and chest computed tomography (CT) imaging…Abstract Number: 1240 • ACR Convergence 2023
Obvious Only in Retrospect: A Cohort of STING Associated Vasculopathy in Infancy (SAVI) Without Typical Rash
Background/Purpose: STING-associated vasculopathy with onset in infancy (SAVI) is characterized by systemic inflammation, skin vasculopathy and interstitial lung disease. However, since the initial description knowledge…Abstract Number: 1704 • ACR Convergence 2023
Esophageal Mucosal Erosions Can Predict the Deterioration of Lung Function over a Four-year Follow-up Period and Long-term Mortality in Patients with Interstitial Lung Disease Associated with Scleroderma
Background/Purpose: Interstitial lung disease (ILD) is a major cause of morbidity and disease-related death in systemic sclerosis (SSc). Esophageal disease is common in SSc, and…Abstract Number: 2140 • ACR Convergence 2023
Serum Alarmins and the Risk of Interstitial Lung Disease in Patients with Rheumatoid Arthritis
Background/Purpose: Alarmins are proteins found in the nuclei of epithelial, endothelial, and immune cells that are released following cell damage and act as stress signals.…Abstract Number: 2594 • ACR Convergence 2023
Trajectories of Forced Vital Capacity (FVC) in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Background/Purpose: The SENSCIS trial enrolled patients with SSc-ILD without a requirement for them to have evidence of recent progression. During the trial, nintedanib reduced the…Abstract Number: 0293 • ACR Convergence 2023
Characteristics and Outcomes of Idiopathic Inflammatory Myositis Associated Interstitial Lung Disease in Rural Appalachia
Background/Purpose: Interstitial lung disease (ILD) can affect up to 30% of the patients with idiopathic inflammatory myositis (IIM) and contributes significantly towards morbidity and mortality…Abstract Number: 0644 • ACR Convergence 2023
Prediction of Stable SSc-ILD Depends on Definition of ILD Progression
Background/Purpose: Progression of interstitial lung disease (ILD) reduces long-term survival in patients with systemic sclerosis (SSc), and aggressive treatment and tight monitoring should be considered.…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 39
- Next Page »